Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jay Achar, Cathy Hewison, Ana P. Cavalheiro, Alena Skrahina, Junia Cajazeiro, Parpieva Nargiza, Krzysztof Herboczek, Assliddin S. Rajabov, Jennifer Hughes, Gabriella Ferlazzo, James A. Seddon, Philipp du Cros
Format:	Artigo
Idioma:	Inglês
Publicat:	Centers for Disease Control and Prevention 2017-10-01
Col·lecció:	Emerging Infectious Diseases
Matèries:	MDR TB XDR TB pediatric treatment bedaquiline tuberculosis
Accés en línia:	https://wwwnc.cdc.gov/eid/article/23/10/17-0303_article
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!